31P-MRS directly assesses metabolites linked to cellular metabolism, which may be altered at the early stages of Alzheimer’s disease (AD). A major challenge for 31P-MRS is the low sensitivity of the 31P nucleus. Therefore, 31P-MRS has only been used sporadically in AD research. To address this, we built a highly-sensitive dual-nuclei (31P/1H) radio frequency coil array and acquired whole-brain 31P-MRS data from cognitive normal subjects at increased risk for AD, who had previously received FDG and amyloid-PET evaluations. Our goal was to detect energetic abnormalities in this pre-clinical population and compare 31P-MRS findings with established PET-based biomarkers of AD.